University of Kentucky

UKnowledge
Theses and Dissertations--Public Health (M.P.H.
& Dr.P.H.)

College of Public Health

2019

KY Stroke Encounter Quality Improvement Project: An Evaluation
of the Differential Administration of tPA in Acute Ischemic Stroke
Payton Malone
University of Kentucky, payton.malone@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/cph_etds
Part of the Public Health Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Malone, Payton, "KY Stroke Encounter Quality Improvement Project: An Evaluation of the Differential
Administration of tPA in Acute Ischemic Stroke" (2019). Theses and Dissertations--Public Health (M.P.H. &
Dr.P.H.). 261.
https://uknowledge.uky.edu/cph_etds/261

This Graduate Capstone Project is brought to you for free and open access by the College of Public Health at
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.) by an
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my capstone and abstract are my original work. Proper attribution has been
given to all outside sources. I understand that I am solely responsible for obtaining any needed
copyright permissions. I have obtained needed written permission statement(s) from the
owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic
distribution (if such use is not permitted by the fair use doctrine) which will be submitted to
UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s capstone including
all changes required by the advisory committee. The undersigned agree to abide by the
statements above.
Payton Malone, Student
Dr. Teresa Waters, Committee Chair
Sarah Wackerbarth, PhD, Director of Graduate Studies

KY Stroke Encounter Quality Improvement Project: An Evaluation of the
Differential Administration of tPA in Acute Ischemic Stroke
Payton Malone
B.S., Eastern Kentucky University, 2014

A Capstone Project
Submitted in Partial Fulfillment of the
Requirements for the Degree of Master of Public Health
at the
University of Kentucky
2019

Payton Malone – Capstone

Objective
The purpose of this study was to identify differences in administration of tPA in the state of
Kentucky by patient characteristics using Kentucky Stroke Encounter Quality Improvement
Project (KY SEQIP) data.

Introduction
Cerebrovascular disease (stroke) was the third leading cause of death in the United States less
than 20 years ago (Jauch et al., 2013) but various medical advancements have allowed for
significantly improved stroke mortality over the past two decades and it is now the fifth leading
cause of death in the country (Heron, 2018). Despite these advances and the fact that overall
mortality attributed to stroke has improved, mortality rates for specific populations differ. For
instance, stroke is the fifth leading cause of death for men (and overall) but remains third in
women. In non-Hispanic whites, stroke is the fifth leading cause of death, but third in the nonHispanic black population (Heron, 2018). These data illustrate the need to further describe and
understand the possible reasons for mortality differences among populations and define whether
these differences represent health disparities in stroke care quality.

Kentucky mirrors the overall stroke mortality trend, with stroke as the fifth leading cause of
death in the state but continues to underperform in relation to American Heart
Association/American Stroke Association (AHA/ASA) guidelines overall (Moore, Merritt,
Bobo, Graham, & Kuhn, 2019). Importantly, Kentucky is one of eight to ten states included in
the definition of the “stroke belt” - an area of the United States with abnormally high incidence
of stroke and associated mortality. Other states include Tennessee, Arkansas, Alabama,
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Mississippi, Louisiana, Georgia, South Carolina, and North Carolina (Howard et al., 2005) (Karp
et al., 2016) (Ingram, 2015).
The Kentucky Department for Public Health (KDPH) is required by KRS 211.575 to “implement
a plan to address continuous quality improvement for stroke care” (Moore et al., 2019)
("Statewide system for stroke response and treatment," 2012). In 2009, the Kentucky Heart
Disease and Stroke Prevention Task Force – Cardiovascular Health (CVH) Delivery Systems
Subcommittee in partnership with the AHA/ASA created KY SEQIP. This is a statewide
voluntary stroke registry for acute care hospitals in the state that tracks evidence-based stroke
achievement measures. As a part of KRS 211.575, KDPH is also responsible for producing a
summary report related to these measures to be presented to the governor and Legislative
Research Commission (LRC) on an annual basis.

Stroke achievement measures described by the AHA for ischemic stroke include early
presentation to a stroke center and administration of IV tPA, early antithrombotics, and venous
thromboembolism (VTE) prophylaxis. (AHA/ASA, 2018) Reporting hospitals currently track
and report 10 evidence-based performance measures (Table 1) from AHA/ASA as well as other
stroke patient information. A full list of guidelines and recommendations for use of tPA is
available elsewhere (Powers et al., 2018).

KY SEQIP’s overall mission is to “advance acute stroke care management and reduce stroke
disparities.” The program seeks to achieve this in Kentucky by:
1. Establishing a network of professionals that will encourage and support collaboration
among stroke care providers in Kentucky.
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2. Providing opportunities to share information and resources related to stroke program
development and proficiency across the continuum of care in Kentucky.
3. Promoting quality, improving outcomes, and standardization of acute stroke care through
collegiality and use of evidence-based practice guidelines.
4. Collaborating on stroke related research throughout Kentucky. (Kentucky Cabinet for
Health and Family Services & Berrones, 2018)
KY SEQIP data capture
approximately 80% of all
strokes that occur in the
state of Kentucky. The
Centers for Disease
Control and Prevention as

Table 1: Evidence-based performance measures tracked by KY SEQIP, endorsed by
AHA/ASA
1. Alteplase (IV tPA) administration - administering the only FDA approved clot busting
drug to eligible patients.
2. Early Antithrombotics – administering medications by the end of hospital day two that help
prevent strokes from reoccurring by keeping products in the blood from sticking together.
3. Venous Thromboembolism (VTE) Prophylaxis – administering medications or applying
pulsating sleeves to the legs that assist with pumping blood flow back to the heart and decrease
the risk of blood clot formation in the legs.
4. Antithrombotics at Discharge – prescribing medications at discharge that help prevent strokes
from reoccurring by keeping products in the blood from sticking together.

well as the AHA/ASA are

5. Anticoagulation for Atrial Fibrillation/Flutter – administering medications at discharge that
thin the blood and prevent blood clots from forming for those patients with the abnormal heart
rhythm of atrial fibrillation or flutter

responsible for data

6. Smoking Cessation – All stroke patients who smoke should receive counseling and be notified
of resources available to assist them in their efforts to stop smoking.

quality control and the

7. Low Density Lipoprotein (LDL) - All patients with an LDL (bad cholesterol that contributes
to plaque build-up in the arteries) should be prescribed a statin (medication that prevents
cholesterol and plaque build-up) at discharge unless contraindicated.

Kentucky Department for

8. Dysphagia Screen – All stroke patients safe swallowing ability should be assessed before
giving pills, food, or liquids by mouth to ensure they are not going into the lungs.

Public Health (KDPH)

9. Stroke Education – All stroke patients or their caregivers should be educated on the signs and
symptoms of stroke, their personal risk factors for stroke, medications prescribed for stroke
prevention, activation of 911 for stroke symptoms, and follow up appointments

releases annual summaries
of the database each year.

10. Rehabilitation Considered – physical therapists, occupational therapists, and speech language
pathologists should evaluate patients and assist in the decision making for most appropriate
discharge location and plan.

One main focus of the KY SEQIP database is tracking the use of intravenous recombinant tissue
plasminogen activator (tPA) as this is one of the only promising treatment options for patients
experiencing ischemic stroke. tPA is a clot busting drug that was first approved for use in
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myocardial infarction in 1986 and was approved for use in acute ischemic stroke a decade later
(1996), following a National Institute of Neurological Disorders and Stroke study demonstrating
the efficacy of tPA in ischemic stroke when used within three hours of symptom onset. (rtPA
Stroke Study Group, 1995). This study served as the basis for a three-hour time window
recommendation for administration of tPA. That timeframe was extended to 4.5 hours following
the European Cooperative Acute Stroke Study III (ECASS III) in 2008 (Davis & Donnan, 2009).
Beyond ischemic stroke and myocardial infarction, other indications for tPA include pulmonary
embolism and IV catheter occlusion (Hughes, Tadi, & Bollu, 2019).

IV tPA administration within 4.5 hours of onset of stroke symptoms and door-to-needle time
(DNT) in under 60 minutes are both Class I recommendations for use in ischemic stroke as
determined by the AHA/ASA. The administration timeframe is measured from the time the
patient was last known to be well (also referred to as last known normal, LKN). Other factors
that impact medical decision-making regarding stroke therapy are mainly derived from the
patient’s medical history. Early administration of tPA is the standard of care for ischemic stroke
though there are a number of contraindications to its use. Some of these include significant head
trauma or stroke within the previous three months, recent intracranial or intraspinal surgery, and
anticoagulant use (Powers et al., 2018).

tPA is useful only for ischemic stroke (and will exacerbate hemorrhagic stroke); in order to use
the drug, the type of stroke must be known by the provider. Type of stroke can be ascertained
through a combination of the history of present illness and imaging. Thus, brain imaging (most
commonly non-contrast computed tomography) is a requirement for tPA administration, which is
pertinent to the current study as door-to-imaging time (DIT) is of vital importance to DNT and,
5
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consequently, efficient administration of tPA. National guidelines for DIT and DNT are 25
minutes and 60 minutes, respectively.

Though the benefits of early administration of tPA are well-known, and despite improvement in
tPA administration rates for eligible patients (Schwamm et al., 2013), not everyone who is
eligible to receive tPA does. A recent analysis of over 60,000 acute ischemic stroke patients
determined that about a quarter of patients eligible to receive tPA did not (Messe et al., 2016). A
separate study examining the experience of 126,795 stroke patients for DIT determined that only
41.8% of patients seen in the ED for ischemic stroke were imaged within the recommended 25
minutes. Not surprisingly, patients with better DIT are also more likely to be treated with tPA.
Variables associated with a lower likelihood of appropriate DIT, and thus, less likely to receive
tPA included: “age (70 years); female gender; nonwhite race; history of diabetes, peripheral
vascular disease, or prosthetic heart valve; transportation to ED other than EMS; time between
symptom onset and ED arrival 60 minutes; and hospital location in the Northeast” (Kelly,
Hellkamp, Olson, Smith, & Schwamm, 2012). These are some of the same variables known to be
associated with overall likelihood of receiving tPA as well.

Stroke care quality improvement initiatives over the last two decades have focused on the
guidelines described above. Administration of tPA including evaluations of DIT, DNT, overall
frequency of administration, and modifying factors are the main focus of most recent quality
improvement campaigns. On the whole, stroke quality improvement projects initiated by the
AHA/ASA such as Get With the Guidelines: Stroke and the AHA/ASA Target: Stroke campaign
have been effective in improving stroke mortality (Fonarow et al., 2014; McDermott, Skolarus,
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& Burke, 2019) (Saver et al., 2013). Much of the success related to improved stroke mortality
can be attributed to the use of intravenous tPA and stroke management improvement initiatives
with that specific aim (Schwamm et al., 2013).

In this study, we seek to characterize patients who do and do not receive tPA in Kentucky in
order to identify potential differences as well as opportunities for improvement and targeted
interventions.

Methods
This was a retrospective secondary data analysis of ischemic stroke patients included in the KY
SEQIP database between from 2009 - 2018.

Study Sample
As an initiative to improve stroke care in the state, KY SEQIP was created in 2009. It is a
voluntary stroke registry for hospitals in Kentucky. Those hospitals with current stroke center
designation or seeking such designation from AHA/ASA and Joint Commission are included
(Appendix 1). Due to the number and type of hospitals included in the KY SEQIP database, it is
estimated that these data capture about 80% of all strokes that occur in Kentucky (population
4.47 million as of 2017 [Bureau, 2019]) each year.

There are four stroke center designations issued by the Joint Commission and AHA/ASA. Those
designations are (in order beginning with highest level of certification): (1) Comprehensive
Stroke Certification; (2) Thrombectomy-Capable Stroke Certification; (3) Primary Stroke Center
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and; (4) Acute Stroke ready Hospital Certification. The state of Kentucky boasts 20 primary
stroke centers, 3 acute stroke ready hospitals, and four comprehensive stroke centers; two in
Lexington and two in the Louisville metropolitan area. According to the most recent annual
summary (2018), data from 23 hospitals were included in KY SEQIP database but this number
varies slightly by year. Annual summaries of KY SEQIP data can be requested from KDPH.

The KY SEQIP database includes individual-level data for patients treated in Kentucky stroke
centers that report to KY SEQIP in accordance with the American Heart Association’s “Get with
the Guidelines – Stroke” project. The study sample abstracted from the KY SEQIP database
included 86,978 stroke records between 2008 and 2019.

Data Manipulation
Because the earliest (2008) and most recent (2019) KY SEQIP data do not include complete data
for their respective years, we analyzed data for 2009-2018. We included observations with only
ischemic type stroke (tPA is not indicated otherwise), removed duplicate patient IDs, and only
included the patient’s initial visit in the analytic dataset. Our rationale for including initial visit
alone was that previous stroke drastically impacts eligibility for future use of tPA. We also
excluded observations with missing values for any of the five key variables of interest, including
tPA administration (yes/no), sex (male, female), age, race (black, white, other), and year of
discharge. tPA administration was defined as “yes” if tPA was administered at the institution
reporting or an outside institution. The “other” category of race represented American
Indian/Alaskan native, Asian, Native Hawaiian or Pacific Islander, Hispanic Ethnicity, and those
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listed as “unable to determine.” Age was recoded into six categories: 19-44, 45-54, 55-64, 65-74,
75-84, and 85 and over. Demographics of patients included in the study can be found in Table 2.

Statistical analysis
The remaining observations (n=49,337) were analyzed to characterize differences related to
patient-level variables: tPA administration, sex, age, and race. Six age groups (Table 2) were
used to characterize age-related differences, in keeping with national stroke trend reporting. For
our primary analysis, cross-tabulation was conducted for tPA administration based on sex by age
group, sex by race, and race by age group and bivariate associations were examined using the
chi-square statistic.

Results for all analyses were considered significant if p-values were less than 0.01. All analyses
were performed using SPSS Statistics26.

This study was approved by the University of Kentucky Institutional Review Board.
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Results
Visit records from 49,337 ischemic stroke patients

Figure 1: Selection of Study Sample
54432

Unique initial visit records of
ischemic stroke

were included in our primary analysis (Figure 1).
The majority of our sample was white (87.8%) and

Discharge year incomplete
(2008 and 2019):
4,631

over the age of 65 (62.6%). Nearly one-half of
patients were ages 65-84 (n = 23,778, 48.2% of
population). Males represented 49.4% of the sample

Unknown, sex, race, age, or
tPA treatment status:
464

while females represented 50.6% of the sample. All
49337

Final Sample Size

demographics can be found in Table 2.
Figure 1. Values in red indicate the number of entries removed
from the sample size for primary analysis. Final sample size
included in study was 49,337.

Overall, 10.47% of ischemic stroke patients in this study received tPA. Patient-level factors race
and age were strongly associated with administration of tPA. Notably, this varied by subset
analysis.

tPA administration was similar for males and females (10.74% vs. 10.22%). Among white
patients included in the study, 10.77% received tPA while 7.95% of black patients received tPA
(black race represented 10.10% of sample). All other race/ethnicity groups were included in the
“other” race category which accounted for 2.10% of the sample, of which 10.22% received tPA.
There was a statistically significant difference in tPA administration among the races at p<0.01.
Crosstabulations of subset analyses further characterizing the patterns mentioned are found in
Table 3.
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In all age categories aside from 85 and over, men were more likely to receive tPA compared to
women. White males were more likely (11.03%) to receive tPA than their black counterparts
(8.18%) and other race (10.74%). This pattern was true for females as well. When association of
tPA administration with race was characterized by age the general pattern held with one
exception: in age 75-84 other race was most likely to receive tPA.

tPA administration was significantly associated with sex in the 55-64 age group (males more
likely to receive tPA than females, 11.27% vs. 9.64%, p<0.01) and the 85 and over age group
(females more likely to receive tPA than male, 11.15% vs. 8.47%, p<0.01). Difference in tPA
administration based on race was statistically significant in the following age groups: 45-54, 5564, 65-74, 75-84, 85 and over. The p-values for chi-square statistics for all analyses can be found
in Table 3.
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Table 2. Patient Demographics

Sex

Race

Age

Male

Frequency
(Percent%)
24397 (49.4%)

Female

24940 (50.6%)

Total

49337 (100%)

White

43304 (87.8%)

Black

4996 (10.1%)

Other

Table 3. Rates of tPA Administration by Sex and Age

All (n=49337)

Frequency
(Percent %)
5168 (10.5%)

Male

2619 (10.74%)

Female

2549 (10.22%)

19-44

309 (12.3%)

1037 (2.1%)

45-54

626 (11.2%)

Total

49337 (100%)

55-64

1059 (10.6%)

19-44

2515 (5.1%)

65-74

1205 (10.1%)

45-54

5719 (11.6%)

75-84

1146 (10.1%)

55-64

10219 (20.7%)

85+

726 (10.4%)

65-74

12185 (24.7%)

White

4665 (10.77%)

75-84

11593 (23.5%)

Black

397 (7.95%)

85 +

7106 (14.4%)

Other

106 (10.22%)

Total

49337 (100%)

Sex
Age

Race

p-value

0.062
0.006

<0.001

Table 4. Rates of tPA Administration - Subset Analysis
Frequency (Percent %)
Male
Female

Sex by Age

p-value

19-44

166 (12.88%)

143 (11.66%)

0.354

45-54

388 (11.59%)

255 (10.76%)

0.94

55-64

670 (11.27%)

412 (9.64%)

0.009

65-74

667 (10.36%)

565 (9.83%)

0.33

75-84

541 (10.47%)

628 (9.77%)

0.217

85+

187 (8.47%)

546 (11.15%)

0.001

Male

Female

White

2364 (11.03%)

2301 (10.52%)

0.085

Black

198 (8.18%)

199 (7.73%)

0.556

Other

57 (10.40%)

49 (10.02%)

0.84

White

Black

Other

19-44

244 (12.35%)

56 (12.23%)

9 (10.98%)

0.94*

45-54

548 (11.77%)

78 (8.56%)

17 (11.034%)

0.005*

55-64

942 (11.04%)

117 (7.97%)

23 (10.36%)

<0.001*

65-74

1130 (10.40%)

75 (7.12%)

27 (9.96%)

0.001*

75-84

1093 (10.25%)

53 (7.40%)

23 (10.70%)

0.014*

85+

708 (10.69%)

18 (4.62%)

7 (7.53%)

<0.001*

Sex by Race

Race by Age

*p-values calculated using white and black race only (n=48300)
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Discussion
The results of this study highlight areas for potential improvement in stroke care in Kentucky, as
well as some positive results related to national and state-level stroke care quality improvement
initiatives of the past decade.

Though not always included in the definition of the “Stroke Belt,” Kentucky is often described as
being a part of the southeastern United States, an area known to exhibit alarming discrepancies in
quality of stroke care compared to the rest of the country. “Residents of the southeastern states
are 20%–50% more likely to die of strokes than residents of the rest of the country, but the
Stroke Belt has not been adequately explained by conventional stroke risk factors, social
resources, or medical care access” (Glymour, Kosheleva, & Boden-Albala, 2009). For this
reason, we were interested in the current status of those well-known differences in Kentucky.

Our sample is representative of the state of Kentucky as demographics of patients in this study
largely mirror that of Kentucky’s population on the whole (84.3% white, 8.4% black) (Bureau,
2019) . The demographics of the included stroke patients are consistent with national trends as
2/3 of strokes occur in the elderly (in our study, 62.6% of ischemic strokes occurred in 65 and
over) and the overall current life expectancy in the United States is just under 80 years old
(Kentucky’s is even lower than the national average) (Yang Q, 2017).

Unfortunately, statistics from Kentucky consistently demonstrate that white race is associated
with higher rate of tPA use vs. black race. There is a sizable difference in tPA administration
between black and white patients, (10.77% vs. 7.95%, p<0.01) in the entire sample. Overall, the
13
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pattern holds true for the subsets analyzed in this study including analysis based on sex vs. race
well as age vs. race. Notable differences include female age 19-44 in which black women were
more likely to receive tPA than white women (12.50% vs. 11.35%). It is interesting to note that
rates in younger black patients do not differ from white in youngest populations (Table 3). The
difference in tPA administration rates between black and white race increases with age. It is
unclear whether this is related to health literacy or access to care across the lifespan among age
subgroups.

Disparities are defined by the Institute of Medicine (IOM) as “racial or ethnic differences in the
quality of healthcare that are not due to access-related factors or clinical needs, preferences, and
appropriateness of intervention” (Hebert, Sisk, & Howell, 2008). By this definition, the results of
our study do not necessarily suggest disparities are present. On the other hand, if you take the
Agency for Healthcare Research and Quality’s definition of disparity, that is, “any differences
among populations that are statistically significant and differ from the reference group by at least
10 percent” (Hebert, Sisk, & Howell, 2008) then the difference in tPA administration between
black and white patients (10.77% vs. 7.95%, p<0.01) can easily be called a disparity. This
contrast is meant to illustrate the complexity presented by difference vs. disparity in utilization of
various facets of healthcare. It is unclear whether these data represent inequitable or simply
unequal use of tPA in differing populations. Nonetheless, this determination must be sought after
in order to provide the highest level of care to patients. Though there may be underlying reasons
for these differences and our study is simply correlational, it provides a basis on which to pursue
more detailed and sophisticated research into the topic of racial disparities in stroke treatment.
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As with all of our data, it will be important to further characterize this discrepancy in terms of
tPA eligibility and underlying factors that may contribute to this difference.

Though patients who were white were significantly more likely to receive tPA, eligibility for tPA
was also not considered in this study. In designing future quality improvement initiatives, we
must consider the risk factors related to other races and age. Socioeconomic factors are now
well-known to affect many chronic diseases (Shaw, Theis, Self-Brown, Roblin, & Barker, 2016)
and this may influence the outcome and applicability of this study. Increased prevalence of
severe hypertension in females has been described and implicated as a possibly modifiable risk
factor to address the fact that women historically have not received tPA at the same rate as men
(Madsen et al., 2015). The possibility of similar patterns of under-treatment regarding modifiable
risk factors should be addressed in other populations.

There was no significant difference between the number of male and female patients who
received tPA (10.74% vs. 10.22%) (Table 3). This is an important distinction from previous
literature describing female sex as one factor associated with decreased tPA use (Kelly et al.,
2012). This pattern represents an improvement over previous evidence demonstrating less
desirable quality of stroke care as well as related outcomes in females experiencing ischemic
stroke (Messe et al., 2016). Though not statistically significant, raw frequencies of tPA
administration remain better in males than females. Interestingly, this pattern changes
dramatically in the 85 and over subset of the sample. In this age group, females were
significantly more likely to receive tPA than males (11.15% vs. 8.74%, p<0.01) (Table 4). Males
were more likely to receive tPA in every other age group. This could be attributed to a form of
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survivorship bias. It is possible that factors responsible for the change in pattern of sexdifferentiated tPA administration are the same that contribute to higher life expectancy in
females. In the US, female life expectancy is five years longer than males (76.1 vs. 81.1) (Arias,
2019). Men surviving into old age can be assumed to be less healthy on the whole than agematched females which can impact eligibility.

In general, patients were less likely to receive tPA as age increased. This is generalizable across
black and white race as well as sex. This pattern is not as clear in the “other” category of race,
which may be attributed to smaller sample size in the subsamples as “other” race made up only
2.1% of the total sample size.

Future Studies
To further characterize the use of tPA in stroke centers around Kentucky, it will be essential for
future studies to take into consideration eligibility for use, confounding factors such as race and
socioeconomic status that may affect the overall health of a patient and likelihood they may
receive tPA. Though our study does not define why the black population is less likely to receive
tPA as often as white, it does confirm that a disappointing trend in Kentucky. Whether risk
factors are higher and eligibility lower or if it is discrimination on the part of the physician,
hospital staff, or due to source of insurance, something needs to be improved in order to increase
access to lifesaving treatment and provide the possibility of possible outcomes for all
demographics within the state.

16

Payton Malone – Capstone
To that end, the next study utilizing these data will better define source of insurance and we will
identify and characterize disparities based on zip code. Zip code was not a data point regularly
imported into the database until recent years. Thus, the sample for the upcoming study will be
smaller but could provide more evidence to the current notion in public health that your zip code
defines as much or more about your health than any other factor (Graham, 2016) (Slade-Sawyer,
2014). We aim to characterize that reality in stroke care, a leading cause of morbidity and
mortality in Kentucky.

One “strength of the data” listed in the yearly KY SEQIP overview produced by KDPH notes the
recording of the National Institutes of Health Stroke Scale score and Modified Rankin scores.
These data were not used for the present study but will also be considered in the future for
purposes of more clearly defining eligibility for tPA and understanding the severity of strokes we
are dealing with.

Limitations
Limitations of Database
This study has a number of limitations which restrict the conclusions that can be drawn from it,
though the data still provide an illustration of patterns that may act as points of possible
intervention. There are inherent limitations in any secondary study. This study’s limitations are
due mainly to the nature of the Kentucky Stroke Encounter Quality Improvement Project
database used. First and foremost, this is not a database originally designed for research. Data
collection and management tools used by the AHA/ASA and KDPH limit the use of this for
these purposes. The codebook is not created by the same entity that creates and maintains the
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database and though it is based on the American Heart Association’s Get with the Guidelines –
Stroke program, these data were not collected using a uniform process throughout the studied
years.

As with any secondary study, there were missing data as well as extraneous variables to be
considered by the researchers (e.g. extreme ages representing improperly entered data). It is
unknown how these incongruences affect the outcome of the study or validity of results as it is
unknown if they represent any pattern of collection related to the quality of care patients
received, tPA eligibility, or other confounding factors. Data are also entered by a single
abstractor looking at electronic health record (EHR) of individual patients at each study location,
thus, human error must be considered plausible and likely. Further, the EHR is not necessarily a
good source of data for all variables, such as source of insurance, which we were not able to
include in this study due to concerns about validity of the variable.

Limitations of Specific Study Variables
In the case of duplicate patient ID, researchers chose to analyze only initial visit based on
professional opinion as recurrent stroke will have an impact on eligibility for tPA. This study
does not characterize patient eligibility for tPA. Exclusion criteria not taken into consideration.

An original goal of the study was to assess the relationship between source of insurance and use
of tPA but this was encumbered by uncertainty about database entries. It was very difficult to
properly analyze these data and information regarding source of data was not entered for many
of the patient visits (some of which could actually represent no insurance source). Further, since
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the collection forms used include a “check all that apply” designation for source of insurance, it
was unknown which source was the “primary” source of insurance for these patients and this
likely led to an inaccurate representation of the study results. This will be something we work on
with KDPH and AHA/ASA. A better method for defining this variable is much-needed.

Further, the data points extracted from patient records in the hospitals participating in KY SEQIP
are determined by the AHA/ASA based on the status of their Get With the Guidelines program.
There is no schedule for these changes as they are adjusted based on the current literature and
evidence. The specifics of the current Get With The Guidelines stroke guidelines for quality
stroke care can be found on the AHA/ASA website at www.heart.org. The initiatives for stroke
centers have entered Phase III of the Target:Stroke program.

Recommendations
Overall, we encourage the organizations partnered with KY SEQIP to focus on making the
survey data useful for research. Insurance data should be extracted from proper source (billing)
instead of EHR. Care should be taken and emphasis placed upon consistent recording and
maintenance of data each year by doing the following:


Provide codebook for each year



Use uniform survey each year
o Provide report of what has changed each year on survey



Produce aggregate data
o Years of data with which hospitals participated
o Reporting percentages
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Annual report: Maintain consistent language (i.e. “UK Healthcare” vs. “University of
Kentucky Hospital”)



Create variable for eligibility of tPA



Source of insurance needs to be more well-described and taken from reliable source
(billing)
o Create a variable for primary insurance source
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Appendix 1
SEQIP Hospitals (Kentucky Heart Disease and Stroke Prevention Program
SEQIP Stroke Registry 2016 Data Summary)
1. All SEQIP hospitals
2. Baptist Health Floyd
3. Baptist Health Louisville
4. Baptist Health LaGrange
5. Baptist Health Lexington
6. Baptist Health Paducah
7. Cardinal Hill Rehab Hospital
8. Ephraim McDowell Regional Medical Center
9. Fleming County Hospital
10. Frankfort Regional Medical Center
11. Georgetown Community Hospital
12. Greenview Regional Hospital
13. Hardin Memorial Health
14. Harlan ARH
15. Highlands Regional Medical Center
16. Jackson Purchase Medical Center
17. Jewish Hospital
18. King’s Daughter’s Medical Center
19. Lake Cumberland Regional Hospital
20. Morgan County ARH
21. Norton Audubon Hospital
22. Norton Brownsboro Hospital
23. Norton Hospital
24. Norton Women’s and Children’s Hospital
25. Our Lady Of Bellefonte Hospital
26. Owensboro Health Regional Hospital
27. Pikeville Medical Center
28. Saint Joseph Hospital
29. St Elizabeth Edgewood
30. St Elizabeth Florence
31. St Elizabeth Ft Thomas
32. Sts. Mary and Elizabeth Hospital
33. The Medical Center at Bowling Green
34. Three Rivers Medical Center
35. University of Kentucky Hospital
36. University of Louisville Hospital
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